메뉴 건너뛰기




Volumn 6, Issue 9, 2010, Pages 566-569

Emerging medical therapies for the treatment of GERD

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; LESOGABERAN; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RIMONABANT; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

EID: 77958531623     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (3)

References (6)
  • 1
    • 77955502520 scopus 로고    scopus 로고
    • Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease
    • Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology. 2010;139:409-417.
    • (2010) Gastroenterology , vol.139 , pp. 409-417
    • Boeckxstaens, G.E.1    Beaumont, H.2    Mertens, V.3
  • 2
    • 68849117968 scopus 로고    scopus 로고
    • A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
    • Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut. 2009;58:1192-1199.
    • (2009) Gut , vol.58 , pp. 1192-1199
    • Keywood, C.1    Wakefield, M.2    Tack, J.3
  • 3
    • 77954708210 scopus 로고    scopus 로고
    • Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease
    • Calabrese C, Spisni E, Liguori G, et al. Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;32:603-611.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 603-611
    • Calabrese, C.1    Spisni, E.2    Liguori, G.3
  • 4
    • 77955081953 scopus 로고    scopus 로고
    • GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease
    • Lehmann A, Jensen JM, Boeckxstaens GE. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol. 2010;58:287-313.
    • (2010) Adv Pharmacol , vol.58 , pp. 287-313
    • Lehmann, A.1    Jensen, J.M.2    Boeckxstaens, G.E.3
  • 5
    • 77953232099 scopus 로고    scopus 로고
    • Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease
    • Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2010;105:1266-1275.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1266-1275
    • Gerson, L.B.1    Huff, F.J.2    Hila, A.3
  • 6
    • 77958551014 scopus 로고    scopus 로고
    • TRP channels in neurogastroenterology: Opportunities for therapeutic intervention
    • Aug 26. [Epub ahead of print]
    • Boesmans W, Owsianik G, Tack J, Voets T, Berghe PV. TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br J Pharmacol. 2010 Aug 26. [Epub ahead of print].
    • (2010) Br J Pharmacol
    • Boesmans, W.1    Owsianik, G.2    Tack, J.3    Voets, T.4    Berghe, P.V.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.